硅钼杂多阴离子薄膜修饰电极的研究和应用——线性扫描伏安法测定水中可溶性硅酸盐

本文研究了以玻碳电极为基体的1:12硅钼杂多酸根(SiMo_(12)O_(40)~(4-)简称12-MSA)修饰电极的制备及其电化学行为,将12-MSA电极应用于线性扫描伏安法测定天然水中可溶性硅酸盐,结果满意.硅浓度在8.0×10~(-7)～1.7×10~(-3)mol/L,相对标准偏差(n=7)为1.85％,加标回收率为98.2％～103.6％,SiMo_(12)电极具有优良的选择性和稳定性。     

新显色剂1－（对－偶氮苯）－3－（2－噻唑）－三氮烯与锌显色反应的研究及应用

本文研究了新显色剂１－（对－偶氮苯）－３－（２－噻唑）－三氮烯在非离子表面活性剂ＴｒｉｔｏｎＸ－１００存在下，与锌（Ⅱ）显色反应的适宜条件。结果表明，在ｐＨ１３．０～１４．０范围内，锌（Ⅱ）与题示试剂形成１：３的稳定粉红色配合物，其最大吸收波长为５４５ｎｍ，试剂的最大吸收波长为４６３ｎｍ。配合物表现摩尔吸光系数在５４５ｎｍ处为９．６×１０￣４Ｌ·ｍｏｌ￣（－１）＊ｃｍ￣（－１）；０～２４μｇ／２５ｍＬＺｎ符合比耳定律。该试剂对锌的选择性良好。方法用于铝合金中锌的直接测定，结果令人满意。     

Thermal decomposition of 1-ethyl-5-iodotetrazole

The thermal decomposition of 1-ethyl-5-iodotetrazole in a melt and in solutions was studied using thermogravimetry, manometry, pyrolytic mass spectrometry, and IR spectroscopy. The kinetic and activation parameters of the process and the nature of the decomposition products were determined. The reaction mechanism is assumed to involve equilibrium tautomeric rearrangement of the tetrazole to azidoazomethine form followed by homolytic cleavage of the C-I bond.Translated fromIzvestiya Akademii Nauk. Seriya Khimicheskaya, No. 11, pp. 1923–1926, November, 1994.The authors are grateful to O. A. Ivashkevich and P. N. Gaponic (Belarussian State University), who provided the samples of the tetrazole.     

2-芳基硫杂脯氨酸结构特征的研究

对12种2-芳基硫杂脯氨酸进行了红外光谱和核磁共振谱测定,对其中两个化合物作了质谱测定。结果表明,这类化合物固态时主要以两性离子形式存在;有较强的分子离子峰,是一类较稳定的化合物。它们还存在一对非对映异构体,芳环上的取代基对芳环电子云密度的影响较大,而对四氢噻唑环的影响较小。     

Dielectric relaxation studies of 1-hexanol and 1,2-hexanediol in heptane

Solutions of 1-hexanol and 1,2-hexanediol in heptane have been investigated tigated by means of dielectric time domain spectroscopy (TDS). The permittivity spectrum of 1-hexanol in heptane is characterized by a model function containing a sum of three elementary Debye dispersions, while 1,2-hexanediol in heptane is best described by a Cole-Davidson model function. It is shown that dilute solutions of 1-hexanol in heptane have a completely different behavior to that of 1,2-hexanediol. For the diol, the relaxation time levels off at a high value indicating an existence of higher hydrogen bonded complexes. It is possible to quantify the relative amount of monomeric 1-alcohol molecules from the dielectric spectrum. The monomerization rate for 1-hexanol upon dilution with heptane is initially low, but increases rapidly for mole fractions of heptane exceeding 0.4.     

4a,6,7,8a-Tetrahydro-1,3-dithiolo[4',5':5,6]-1,4-dithiino [2,3-b]-1,4-dithiine-2-thione as a precursor for synthesis of new organic π-donors

[2+4[-Cycloaddition of 2,3-dihydro-1,4-dithiine and oligomeric 1,3-dithiol-2,4,5-trithione results in the formation of 4a,6,7,8a-tetrahydro-1,3-dithiolo[4',5':5,61-[1,4[dithiino[2,3-b[1,4-dithiine-2-thione, which is a precursor for synthesis of new organic rz-donors.Translated fromIzvestiya Akademi Nauk Seriya Khimicheskaya No. 3, pp. 775–776, March, 1996.     

铽(Ⅲ)-1,4-双(1′-苯基-3′-甲基-5′-氧代吡唑-4′-基)丁二酮-[1,4]体系荧光性质的研究及应用

本文研究了Tb(Ⅲ)-1,4-双(′-苯基-3′-甲基-5′-氧代吡唑-4′-基)丁二酮-[1,4](BPMPBD)-溴化十六烷基三甲胺(CTMAB)体系的荧光性质,探讨了响影体系荧光性质的诸因素,确定了最佳实验条件。该体系中Tb(Ⅲ)浓度以2.0×10~(-5)～1.0×10~(-10)mol/L范围内与其荧光强度呈线性关系,检测限可达到5.0×10~(-11)mol/L。应用于合成样品中微量Tb(Ⅲ)的分析,结果令人满意。     

Protein-ligand binding free energy estimation using molecular mechanics and continuum electrostatics. Application to HIV-1 protease inhibitors

A method is proposed for the estimation of absolute binding free energy of interaction between proteins and ligands. Conformational sampling of the protein-ligand complex is performed by molecular dynamics (MD) in vacuo and the solvent effect is calculated a posteriori by solving the Poisson or the Poisson-Boltzmann equation for selected frames of the trajectory. The binding free energy is written as a linear combination of the buried surface upon complexation, SASbur, the electrostatic interaction energy between the ligand and the protein, Eelec, and the difference of the solvation free energies of the complex and the isolated ligand and protein, deltaGsolv. The method uses the buried surface upon complexation to account for the non-polar contribution to the binding free energy because it is less sensitive to the details of the structure than the van der Waals interaction energy. The parameters of the method are developed for a training set of 16 HIV-1 protease-inhibitor complexes of known 3D structure. A correlation coefficient of 0.91 was obtained with an unsigned mean error of 0.8 kcal/mol. When applied to a set of 25 HIV-1 protease-inhibitor complexes of unknown 3D structures, the method provides a satisfactory correlation between the calculated binding free energy and the experimental pIC5o without reparametrization.     

Metabolomic-based investigation of Yinlan alleviating hyperlipidemia by inhibiting blood stasis and phlegm turbidity through the PXR-CYP3A4-ABCB1-FXR pathway

Yinlan lipid regulatory capsule (YL) is a composite traditional Chinese medicine (TCM) new drug to alleviate hyperlipidemia, while its therapeutic mechanism in vivo was not clarified with nontargeted metabolomics investigation. An animal model was established in rats fed a high-fat diet, and their body weights, body mass index (BMI) and blood cholesterol levels were measured. Serum, liver and kidney tissue samples were also extracted for PXR-CYP3A4-ABCB1-FXR signaling pathway research using PCR and UHPLC–MS. The obtained plasma samples were analyzed by UHPLC-Q-TOF-MS metabolomic investigation, which revealed PXR-CYP3A4-related metabolites and changes induced by YL. Finally, the key metabolites were chosen as index components, and their levels in the serum, liver, small intestine and bile were used for simultaneous UHPLC–MS-MS determination. The results indicated that YL was effective in rebalancing blood TG and TC levels (compared to controls). With respect to the PXR-CYP3A4-ABCB1 pathway, as a result of YL’s effect, gene expression or activity of the two targets decreased significantly in both the liver and kidney. The same trend was observed in the serum samples mentioned above. Metabolomics screening and data revealed that 44 metabolites can be regarded as biomarkers related to hyperlipidemia, fatty acids synthesis, and body energy consumption, as well as synthesis, transportation and exertion of cholesterol. YL’s treatment focused on 26 of them, primarily bile acids, indicating that the antihyperlipidemic effect of this drug lies in its inhibitory activity of cholesterol metabolism. Subsequent analysis of those in vivo components revealed that significant increases (compared to the model group) occurred in the blood, liver, small intestine and bile in groups that received medium and high doses of YL (while the low dose was relatively unchanged). Those target components exhibit a close relationship with PXR and/or CYP3A4. The use of YL repressed PXR expression and subsequently decreased CYP3A4 activity. As a result, synthesis of related bile acids increased, while cholesterol levels decreased, consequently leading to the attenuation of hyperlipidemia. This study comprehensively investigated the antihyperlipidemia mechanism of YL based on its repression of PXR-CYP3A4 activity and related metabolite yield, establishing an accurate method for evaluating the therapeutic effect of YL.